Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CALADRIUS BIOSCIENCES, INC.

(CLBS)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/20/2021 09/21/2021 09/22/2021 09/23/2021 09/24/2021 Date
1.19(c) 1.18(c) 1.2(c) 1.22(c) 1.22(c) Last
388 659 209 273 232 246 296 668 180 761 Volume
-0.83% -0.84% +1.69% +1.67% 0.00% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 - - -
Net income 2021 -32,3 M - -
Net Debt 2021 - - -
P/E ratio 2021 -2,14x
Yield 2021 -
Sales 2022 8,75 M - -
Net income 2022 -28,2 M - -
Net Debt 2022 - - -
P/E ratio 2022 -3,01x
Yield 2022 -
Capitalization 72,6 M 72,6 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 8,30x
Nbr of Employees 24
Free-Float 96,3%
More Financials
Company
Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is developing therapeutics based on the characteristics of naturally occurring CD34+ cells. Its product candidates include CLBS16, the subject of both a positive Phase IIa study and Phase IIb (FREEDOM) study in the United States for the treatment of coronary microvascular dysfunction (CMD); HONEDRA (CLBS12), recipient of SAKIGAKE... 
More about the company
All news about CALADRIUS BIOSCIENCES, INC.
09/08CALADRIUS BIOSCIENCES : to Present at the H.C. Wainwright 23rd Annual Global Investment Co..
AQ
09/01CALADRIUS BIOSCIENCES : Announces Appointment of Kristen K. Buck, M.D., as Chief Medical O..
AQ
09/01Caladrius Biosciences Announces Appointment of Kristen K. Buck as Chief Medical Officer
CI
08/05CALADRIUS BIOSCIENCES : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RE..
AQ
08/05CALADRIUS BIOSCIENCES, INC. : Regulation FD Disclosure, Financial Statements and Exhibits ..
AQ
08/05Caladrius Biosciences Reports Second Quarter 2021 Financial Results and Provides Busine..
GL
08/05Caladrius Biosciences, Inc. Reports Earnings Results for the Second Quarter Ended June ..
CI
08/02CALADRIUS BIOSCIENCES : Chardan Suspends Coverage on Caladrius Biosciences at Buy Rating W..
MT
07/29CALADRIUS BIOSCIENCES TO HOST SECOND : 30 p.m. Eastern Time
GL
07/22Caladrius Biosciences to Present at Zooming with LD
GL
06/22CALADRIUS BIOSCIENCES : to Move Forward With Clinical Program for CLBS201 in Diabetic Kidn..
MT
06/22Caladrius Biosciences to Assess its CLBS201 CD34+ Cell Therapy in Diabetic Kidney Disea..
GL
06/22Caladrius Biosciences to Assess Its CLBS201 CD34+ Cell Therapy in Diabetic Kidney Disea..
CI
06/17CALADRIUS BIOSCIENCES : to Present at Noble Capital Markets Virtual Investor Forum during ..
AQ
06/16CALADRIUS BIOSCIENCES, INC. : Submission of Matters to a Vote of Security Holders (form 8-..
AQ
More news
News in other languages on CALADRIUS BIOSCIENCES, INC.
2018Société Générale signe un accord pour la vente de sa filiale serbe à OTP Banque
More news
Analyst Recommendations on CALADRIUS BIOSCIENCES, INC.
More recommendations
Chart CALADRIUS BIOSCIENCES, INC.
Duration : Period :
Caladrius Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CALADRIUS BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 1,22 $
Average target price 10,00 $
Spread / Average Target 720%
EPS Revisions
Managers and Directors
David J. Mazzo President, Chief Executive Officer & Director
Greg B. Brown Chairman
Gregory S. Berkin Chief Information Officer, VP-Cybersecurity & IT
Kristen K. Buck Chief Medical Officer
Steven S. Myers Independent Director
Sector and Competitors
1st jan.Capi. (M$)
CALADRIUS BIOSCIENCES, INC.-14.69%73
MODERNA, INC.311.74%173 624
LONZA GROUP AG30.56%59 611
IQVIA HOLDINGS INC.46.01%50 128
CELLTRION, INC.-23.54%31 745
SEAGEN INC.-7.88%29 353